Several preclinical trials used PDXMs to evaluate targeted therapy for thyroid cancer, including vemurafenib for PTC, the selective RET kinase inhibitor LOXO-292 for RET-mutated thyroid cancer, PLX51107 and PD0325901 for ATC, and cabozantinib for MTC [46,47,48,49]. Here, RET is linked to thyroid gland carcinoma.